Nontuberculous mycobacteria among patients with cystic fibrosis in the United States: Screening practices and environmental risk

American Journal of Respiratory and Critical Care Medicine

Volumn 190, Issue 5, 2014, Pages 581-586

  Adjemian, Jennifer ^a   Olivier, Kenneth N ^b   Prevots, D Rebecca ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b U S PUBLIC HEALTH SERVICE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MACROLIDE;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; ATYPICAL MYCOBACTERIUM; BACTERIUM CULTURE; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; DEMOGRAPHY; DRUG USE; GEOGRAPHY; HUMAN; HUMIDITY; MAJOR CLINICAL STUDY; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM COMPLEX; PRECIPITATION; PRIORITY JOURNAL; SCREENING; TEMPERATURE; UNITED STATES; VAPOR PRESSURE; AGED; ATYPICAL MYCOBACTERIOSIS; EPIDEMIOLOGY; MICROBIOLOGY; MIDDLE AGED; PREVALENCE; PULMONARY; REGISTER; RISK FACTOR; SPATIAL; VERY ELDERLY; YOUNG ADULT;

CYSTIC FIBROSIS; EPIDEMIOLOGY; NONTUBERCULOUS MYCOBACTERIA; PULMONARY; SPATIAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CYSTIC FIBROSIS; HUMANS; MIDDLE AGED; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; PREVALENCE; REGISTRIES; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84908146256     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201405-0884OC     Document Type: Article

References (23)

1. Adjemian J, Olivier KN, Seitz A, Holland S, Prevots R. Prevalence of pulmonary nontuberculous mycobacterial infections among U.S. Medicare beneficiaries. Am J Respir Crit Care Med 2012;185:881-886.
2. Mangione EJ, Huitt G, Lenaway D, Beebe J, Bailey A, Figoski M, Rau MP, Albrecht KD, Yakrus MA. Nontuberculous mycobacterial disease following hot tub exposure. Emerg Infect Dis 2001;7:1039-1042.
3. Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, Montes de Oca R, Shea YR, Seitz AE, Holland SM, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med 2010;182:970-976.
4. Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, Saulson A, Hedberg K. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med 2010;182:977-982.
5. Adjemian J, Olivier KN, Seitz AE, Falkinham JO III, Holland SM, Prevots DR. Spatial clusters of nontuberculous mycobacterial lung disease in the United States. Am J Respir Crit Care Med 2012;186:553-558.
6. Olivier KN, Weber DJ, Wallace RJ Jr, Faiz AR, Lee JH, Zhang Y, Brown-Elliot BA, Handler A, Wilson RW, Schechter MS, et al.; Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003;167:828-834.
7. Olivier KN. The natural history of nontuberculous mycobacteria in patients with cystic fibrosis. Paediatric Respir Rev 2004;5(suppl A):S213-S216.
8. Esther CR, Jr., Esserman DA, Gilligan P, Kerr A, Noone PG. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cystic Fibrosis 2010;9:117-123.
9. O'Connell ML, Birkenkamp KE, Kleiner DE, Folio LR, Holland SM, Olivier KN. Lung manifestations in an autopsy-based series of pulmonary or disseminated nontuberculous mycobacterial disease. Chest 2012;141:1203-1209.
10. Olivier KN, Weber DJ, Lee JH, Handler A, Tudor G, Molina PL, Tomashefski J, Knowles MR; Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003;167:835-840.
11. Binder AM, Adjemian J, Olivier KN, Prevots DR. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med 2013;188:807-812.
12. Conza L, Casati S, Limoni C, Gaia V. Meteorological factors and risk of community-acquired Legionnaires' disease in Switzerland: an epidemiological study. BMJ Open 2013;3:pii: e002428.
13. Collaco JM, McGready J, Green DM, Naughton KM, Watson CP, Shields T, Bell SC, Wainwright CE, Cutting GR; ACFBAL Study Group. Effect of temperature on cystic fibrosis lung disease and infections: a replicated cohort study. PLoS ONE 2011;6:e27784.
14. Jaenicke R. Abundance of cellular material and proteins in the atmosphere. Science 2005;308:73.
15. Bowers RM, Clements N, Emerson JB, Wiedinmyer C, Hannigan MP, Fierer N. Seasonal variability in bacterial and fungal diversity of the near-surface atmosphere. Environ Sci Technol 2013;47:12097-12106.
16. Macher J. Bioaerosols: assessment and control. Cincinnati: American Conference of Governmental Industrial Hygienists; 1999.
17. Fisk WJ, Eliseeva EA, Mendell MJ. Association of residential dampness and mold with respiratory tract infections and bronchitis: A meta-analysis. Enviro Health 2010;9:72.
18. Feazel LM, Baumgartner LK, Peterson KL, Frank DN, Harris JK, Pace NR. Opportunistic pathogens enriched in showerhead biofilms. Proc Natl Acad Sci USA 2009;106:16393-16399.
19. Dutil S, Veillette M, Mé riaux A, Lazure L, Barbeau J, Duchaine C. Aerosolization of mycobacteria and legionellae during dental treatment: low exposure despite dental unit contamination. Environ Microbiol 2007;9:2836-2843.
20. Cystic Fibrosis Foundation. Nontuberculous mycobacteria (NTM). 2012 [accessed 2014 Jun 18]. Available from: http://www.cff.org/Adults/Germs/NTM/Treatment/
21. Edwards LB, Acquaviva FA, Livesay VT, Cross FW, Palmer CE. An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am Rev Respir Dis 1969;99(suppl):1-132.
22. Grif fith DE, Aksamit TR. Therapy of refractory nontuberculous mycobacterial lung disease. Curr Opin Infect Dis 2012;25:218-227.
23. Grif fith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al.; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175: 367-416. [Published erratum appears in Am J Respir Crit Care Med 175:744.]